Literature DB >> 32202936

Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary.

Sanjiv J Shah1, Barry A Borlaug2, Dalane W Kitzman3, Andrew D McCulloch4, Burns C Blaxall5, Rajiv Agarwal6, Julio A Chirinos7, Sheila Collins8, Rahul C Deo9, Mark T Gladwin10, Henk Granzier11, Scott L Hummel12, David A Kass13, Margaret M Redfield2, Flora Sam14, Thomas J Wang8, Patrice Desvigne-Nickens15, Bishow B Adhikari15.   

Abstract

Heart failure with preserved ejection fraction (HFpEF), a major public health problem that is rising in prevalence, is associated with high morbidity and mortality and is considered to be the greatest unmet need in cardiovascular medicine today because of a general lack of effective treatments. To address this challenging syndrome, the National Heart, Lung, and Blood Institute convened a working group made up of experts in HFpEF and novel research methodologies to discuss research gaps and to prioritize research directions over the next decade. Here, we summarize the discussion of the working group, followed by key recommendations for future research priorities. There was uniform recognition that HFpEF is a highly integrated, multiorgan, systemic disorder requiring a multipronged investigative approach in both humans and animal models to improve understanding of mechanisms and treatment of HFpEF. It was recognized that advances in the understanding of basic mechanisms and the roles of inflammation, macrovascular and microvascular dysfunction, fibrosis, and tissue remodeling are needed and ideally would be obtained from (1) improved animal models, including large animal models, which incorporate the effects of aging and associated comorbid conditions; (2) repositories of deeply phenotyped physiological data and human tissue, made accessible to researchers to enhance collaboration and research advances; and (3) novel research methods that take advantage of computational advances and multiscale modeling for the analysis of complex, high-density data across multiple domains. The working group emphasized the need for interactions among basic, translational, clinical, and epidemiological scientists and across organ systems and cell types, leveraging different areas or research focus, and between research centers. A network of collaborative centers to accelerate basic, translational, and clinical research of pathobiological mechanisms and treatment strategies in HFpEF was discussed as an example of a strategy to advance research progress. This resource would facilitate comprehensive, deep phenotyping of a multicenter HFpEF patient cohort with standardized protocols and a robust biorepository. The research priorities outlined in this document are meant to stimulate scientific advances in HFpEF by providing a road map for future collaborative investigations among a diverse group of scientists across multiple domains.

Entities:  

Keywords:  diagnosis; heart failure; precision medicine; therapeutics

Mesh:

Year:  2020        PMID: 32202936      PMCID: PMC7101072          DOI: 10.1161/CIRCULATIONAHA.119.041886

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  113 in total

1.  Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial.

Authors:  Barry A Borlaug; Kevin J Anstrom; Gregory D Lewis; Sanjiv J Shah; James A Levine; Gabe A Koepp; Michael M Givertz; G Michael Felker; Martin M LeWinter; Douglas L Mann; Kenneth B Margulies; Andrew L Smith; W H Wilson Tang; David J Whellan; Horng H Chen; Victor G Davila-Roman; Steven McNulty; Patrice Desvigne-Nickens; Adrian F Hernandez; Eugene Braunwald; Margaret M Redfield
Journal:  JAMA       Date:  2018-11-06       Impact factor: 56.272

Review 2.  Heart failure with preserved ejection fraction: molecular pathways of the aging myocardium.

Authors:  Francesco S Loffredo; Andriana P Nikolova; James R Pancoast; Richard T Lee
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

Review 3.  Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: Understanding Mechanisms by Using Noninvasive Methods.

Authors:  Masaru Obokata; Yogesh N V Reddy; Barry A Borlaug
Journal:  JACC Cardiovasc Imaging       Date:  2019-06-12

4.  Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction.

Authors:  Barry A Borlaug; Thomas P Olson; Carolyn S P Lam; Kelly S Flood; Amir Lerman; Bruce D Johnson; Margaret M Redfield
Journal:  J Am Coll Cardiol       Date:  2010-09-07       Impact factor: 24.094

5.  Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction.

Authors:  Venkatesh Y Anjan; Timothy M Loftus; Michael A Burke; Nausheen Akhter; Gregg C Fonarow; Mihai Gheorghiade; Sanjiv J Shah
Journal:  Am J Cardiol       Date:  2012-06-07       Impact factor: 2.778

6.  Arterial Stiffening With Exercise in Patients With Heart Failure and Preserved Ejection Fraction.

Authors:  Yogesh N V Reddy; Mads J Andersen; Masaru Obokata; Katlyn E Koepp; Garvan C Kane; Vojtech Melenovsky; Thomas P Olson; Barry A Borlaug
Journal:  J Am Coll Cardiol       Date:  2017-07-11       Impact factor: 24.094

7.  A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor.

Authors:  M Chinkers; D L Garbers; M S Chang; D G Lowe; H M Chin; D V Goeddel; S Schulz
Journal:  Nature       Date:  1989-03-02       Impact factor: 49.962

8.  Experimentally increasing titin compliance in a novel mouse model attenuates the Frank-Starling mechanism but has a beneficial effect on diastole.

Authors:  Mei Methawasin; Kirk R Hutchinson; Eun-Jeong Lee; John E Smith; Chandra Saripalli; Carlos G Hidalgo; Coen A C Ottenheijm; Henk Granzier
Journal:  Circulation       Date:  2014-03-05       Impact factor: 29.690

9.  Racial differences in circulating natriuretic peptide levels: the atherosclerosis risk in communities study.

Authors:  Deepak K Gupta; Brian Claggett; Quinn Wells; Susan Cheng; Man Li; Nisa Maruthur; Elizabeth Selvin; Josef Coresh; Suma Konety; Kenneth R Butler; Thomas Mosley; Eric Boerwinkle; Ron Hoogeveen; Christie M Ballantyne; Scott D Solomon
Journal:  J Am Heart Assoc       Date:  2015-05-21       Impact factor: 5.501

10.  Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome.

Authors:  Erik B Schelbert; Yaron Fridman; Timothy C Wong; Hussein Abu Daya; Kayla M Piehler; Ajay Kadakkal; Christopher A Miller; Martin Ugander; Maren Maanja; Peter Kellman; Dipan J Shah; Kaleab Z Abebe; Marc A Simon; Giovanni Quarta; Michele Senni; Javed Butler; Javier Diez; Margaret M Redfield; Mihai Gheorghiade
Journal:  JAMA Cardiol       Date:  2017-09-01       Impact factor: 14.676

View more
  70 in total

1.  Renal Denervation to Treat Heart Failure.

Authors:  Thomas E Sharp; David J Lefer
Journal:  Annu Rev Physiol       Date:  2020-10-19       Impact factor: 19.318

2.  Tissue-specific small heat shock protein 20 activation is not associated with traditional autophagy markers in Ossabaw swine with cardiometabolic heart failure.

Authors:  Kleiton Augusto Santos Silva; Emily V Leary; T Dylan Olver; Timothy L Domeier; Jaume Padilla; R Scott Rector; Craig A Emter
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-09-18       Impact factor: 4.733

Review 3.  Heart Failure with Preserved Ejection Fraction: Mechanisms and Treatment Strategies.

Authors:  Kazunori Omote; Frederik H Verbrugge; Barry A Borlaug
Journal:  Annu Rev Med       Date:  2021-08-11       Impact factor: 13.739

Review 4.  Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications.

Authors:  Jun Ren; Ne N Wu; Shuyi Wang; James R Sowers; Yingmei Zhang
Journal:  Physiol Rev       Date:  2021-05-05       Impact factor: 37.312

5.  Salutary Acute Effects of Exercise on Central Hemodynamics in Heart Failure With Preserved Ejection Fraction.

Authors:  Masaru Obokata; Yogesh N V Reddy; Katlyn E Koepp; Glenn M Stewart; Thomas P Olson; Vojtech Melenovsky; Daniel Burkhoff; Barry A Borlaug
Journal:  J Card Fail       Date:  2021-05-08       Impact factor: 5.712

Review 6.  From Systemic Inflammation to Myocardial Fibrosis: The Heart Failure With Preserved Ejection Fraction Paradigm Revisited.

Authors:  Walter J Paulus; Michael R Zile
Journal:  Circ Res       Date:  2021-05-13       Impact factor: 17.367

7.  The right ventricular transcriptome signature in Ossabaw swine with cardiometabolic heart failure: implications for the coronary vasculature.

Authors:  Shannon C Kelly; Christoph D Rau; An Ouyang; Pamela K Thorne; T Dylan Olver; Jenna C Edwards; Timothy L Domeier; Jaume Padilla; Laurel A Grisanti; Bradley S Fleenor; Yibin Wang; R Scott Rector; Craig A Emter
Journal:  Physiol Genomics       Date:  2021-01-25       Impact factor: 3.107

8.  Metabolic inflammation in heart failure with preserved ejection fraction.

Authors:  Gabriele G Schiattarella; Daniele Rodolico; Joseph A Hill
Journal:  Cardiovasc Res       Date:  2021-01-21       Impact factor: 10.787

9.  Myocardial Gene Expression Signatures in Human Heart Failure With Preserved Ejection Fraction.

Authors:  Virginia S Hahn; Hildur Knutsdottir; Xin Luo; Kenneth Bedi; Kenneth B Margulies; Saptarsi M Haldar; Marina Stolina; Jun Yin; Aarif Y Khakoo; Joban Vaishnav; Joel S Bader; David A Kass; Kavita Sharma
Journal:  Circulation       Date:  2020-10-29       Impact factor: 29.690

10.  Go Red for Women Strategically Focused Research Network: Summary of Findings and Network Outcomes.

Authors:  Marie-Pierre St-Onge; Brooke Aggarwal; Matthew A Allison; Jeffrey S Berger; Sheila F Castañeda; Janet Catov; Judith S Hochman; Carl A Hubel; Sanja Jelic; David A Kass; Nour Makarem; Erin D Michos; Lori Mosca; Pamela Ouyang; Chorong Park; Wendy S Post; Robert W Powers; Harmony R Reynolds; Dorothy D Sears; Sanjiv J Shah; Kavita Sharma; Tanya Spruill; Gregory A Talavera; Dhananjay Vaidya
Journal:  J Am Heart Assoc       Date:  2021-02-23       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.